Models and methods for studying insurmountable antagonism.
about
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug actionIsolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathwayDiisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors.Modelling of alpha1-adrenoceptor-mediated temporal dynamics of inotropic response in rat heart to assess ligand binding and signal transduction parameters.Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Drug-target residence time--a case for G protein-coupled receptors.On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targetsEstimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.Nitro-oleic acid inhibits angiotensin II-induced hypertension.Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors.Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate.Binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor.Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.
P2860
Q24595639-2A208DEE-8BBA-4B85-B4B9-41C0B6063C6EQ33673036-B03E48D2-CE64-49F5-A39D-EE65D948FF53Q34055922-087A63D9-64B4-40B6-9E1E-752C74BB6965Q36146795-6BE70154-4CAA-4D41-8A39-C4FDBCDA1995Q37230836-E9E3C79D-9D9A-48DC-B0E4-083043E926A4Q37803251-717B33E4-2741-48A7-8833-CC12567C881BQ37983747-EE8A7FE4-78E7-43EA-BB98-CD5E4CC545DCQ38189272-F01A56CB-343B-4EC2-80E3-97E694373D85Q38545579-E3884516-A3B0-4492-B508-99C66D632F37Q38710840-4483F1E4-46B1-45F5-8E8F-14B40E44D2E7Q41121806-B05E347A-6B67-4F20-922D-17BA2482C670Q41896971-48D34C06-F2F7-496A-A3FA-FC7307B07321Q42003151-B9CDEC63-E5A4-41F2-B99E-2C4D037EE203Q42428542-81B427B1-4523-4FD9-8F6E-6E09A7035D81Q46077676-C0FE5AA2-AC37-4917-AED0-4FA844D0A836Q50267774-84DF77F6-9E91-41F4-A428-4084616B856FQ51750607-72C4A9BF-ED24-4AED-A492-23F04707C9D3Q52634022-9D4E0F32-A81B-4F9F-9EE3-CA2AEE23C517
P2860
Models and methods for studying insurmountable antagonism.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Models and methods for studying insurmountable antagonism.
@ast
Models and methods for studying insurmountable antagonism.
@en
Models and methods for studying insurmountable antagonism.
@nl
type
label
Models and methods for studying insurmountable antagonism.
@ast
Models and methods for studying insurmountable antagonism.
@en
Models and methods for studying insurmountable antagonism.
@nl
prefLabel
Models and methods for studying insurmountable antagonism.
@ast
Models and methods for studying insurmountable antagonism.
@en
Models and methods for studying insurmountable antagonism.
@nl
P2093
P1476
Models and methods for studying insurmountable antagonism.
@en
P2093
Georges Vauquelin
Isabelle Van Liefde
Patrick Vanderheyden
P304
P356
10.1016/S0165-6147(02)02081-3
P577
2002-11-01T00:00:00Z